North America Large Molecule Drug Substance CDMO Market Size, Share & Industry Trends Analysis Report By Application (Mammalian, Microbial and Others), By Service (Contract Manufacturing and Contract Development), By End-user, By Country and Growth Foreca

North America Large Molecule Drug Substance CDMO Market Size, Share & Industry Trends Analysis Report By Application (Mammalian, Microbial and Others), By Service (Contract Manufacturing and Contract Development), By End-user, By Country and Growth Forecast, 2022 - 2028

The North America Large Molecule Drug Substance CDMO Market would witness market growth of 8.0% CAGR during the forecast period (2022-2028).

In the drug development and pharmacology sectors, molecules are mainly classified as small and large. This difference between the sizes of the molecules also helps in understanding their behavior, transportation or mode of action, suitability, and adaptability for a different forms of drugs.

Presently, most medicines available in the market have been developed from small molecules, but large molecules are rapidly increasing in importance and usability. Drug development from large molecules is divided into drug substance development and drug product development.

The development of drug substance (DS) includes the development of working and master cell banks, scale-up, and manufacturing process development. Drug product (DP) development involves filling the substance into its container. The measurement and characterization guidelines for these processes are provided by the International Council for Harmonization (ICH).

The region collectively spends a lot in the R&D of biopharmaceuticals and, as a result, has become a significant producer of biologics. For example, Canada is among the top manufacturers of vaccines. In addition, some major national and international vaccine-producing firms exist nationwide. Similarly, the US government’s economy is significantly impacted by growing healthcare spending. This has also placed a burden on the populace to support this spending through ways like taxes or long-term borrowing.

The US market dominated the North America Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4,180.9 million by 2028. The Canada market is poised to grow at a CAGR of 10.5% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 9.5% during (2022 - 2028).

Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.

Scope of the Study

Market Segments covered in the Report:

By Application

• Mammalian
• Microbial
• Others

• Contract Manufacturing
• Commercial
• Clinical
• Contract Development
• Cell Line Development
• Process Development

• Biotech Companies
• CRO
• Others

• US
• Canada
• Mexico
• Rest of North America

• Eurofins Scientific SE
• WuXi Biologics (Cayman), Inc
• Catalent, Inc.
• Boehringer Ingelheim International GmbH
• FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
• Samsung Biologics Co., Ltd. (Samsung Group)
• Rentschler Biopharma SE
• AGC Biologics, Inc. (AGC, Inc.)
• Recipharm AB (EQT AB)
• Siegfried Holding AG

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free